ArticleThe oncologist2025
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of methotrexate-associated primary splenic lymphoma diagnosed by endoscopic biopsy of a small gastric lesion.Clinical journal of gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSolid splenic lesions may be the expression of a lymphoproliferative disease spreading to the spleen or appear as the only manifestation of possible neoplastic diseases, mainly hematologic malignancies. Therefore, biopsy is of uttermost importance in clarifying their nature. PATIENTS AND
methodsForty-four patients with splenic nodular lesions suspected of hematologic disease underwent spleen contrast-enhanced ultrasonography and contextual biopsy using an 18-gauge needle. All procedures were performed on an outpatient basis. Patients with inconclusive findings or with a diagnosis of unaffected splenic tissue were followed up to discriminate between true and false-negative results.
resultsAll procedures ended up with sampling of splenic tissue without severe complications requiring hospitalization or supportive countermeasures. None was interrupted because of adverse event (AE)s. Out of 44 samples, a final diagnosis was accomplished in 39 cases, with a diagnostic yield of 88.6%. A diagnosis of lymphoma was made in 22 cases. Other diagnoses included: splenic metastases and splenic sarcoma (3 cases each), non-neoplastic lesions (3 cases), and unaffected splenic tissue (8 cases). Among the latter 8 patients, 1 received a diagnosis of Hodgkin lymphoma by marrow biopsy. All the other 7 patients never received a diagnosis of neoplasm and were true negative. Among the 5 patients with insufficient sampling, 3 were never diagnosed with a neoplasm during follow-up; 1 had myelofibrosis and 1 angiosarcoma. The sensitivity of the procedure was 96.6%; specificity was 100% and accuracy was 86.4%.
conclusionsUltrasound-guided core needle biopsy of splenic nodular lesions can be safely performed on an outpatient basis with no severe AEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.